Lv35
378 积分 2023-03-20 加入
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
24天前
已完结
Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer
25天前
已完结
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
25天前
已完结
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis
25天前
已完结
Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review
27天前
已完结
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
1个月前
已完结
Systemic Management of Advanced Adrenocortical Carcinoma
1个月前
已完结
Development and strategies of CDK4/6 inhibitors
1个月前
已完结
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
1个月前
已完结
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
1个月前
已完结
皖公网安备34019202002308
